Ascendis Pharma A/S 6-K Filing

This Form 6-K filing by Ascendis Pharma A/S details new data from their pivotal ApproaCH Trial regarding TransCon CNP (navepegritide) for the treatment of achondroplasia in children. The data, presented at ACMG 2026, shows that children treated with once-weekly TransCon CNP maintained consistent improvements in growth through Week 104, with further improvements in body proportionality during the second year of treatment. TransCon CNP, approved by the U.S. FDA as YUVIWEL® in February 2026 for increasing linear growth in pediatric patients, is a prodrug of C-type natriuretic peptide (CNP). The trial involved 84 children aged 2-11 years over 104 weeks. Results indicated continued improvement in upper-to-lower body segment ratio and consistent treatment benefit in height Z-scores. The drug was generally well-tolerated, with most adverse events being mild and no treatment discontinuations due to adverse events. The Marketing Authorization Application for YUVIWEL is under review by the European Medicines Agency, with a decision anticipated in Q4 2026. The filing also includes forward-looking statements regarding the drug's potential, regulatory timelines, and various risks and uncertainties associated with Ascendis' operations and the pharmaceutical industry.